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SCREENING AND CHARACTERIZATION OF A PAN-GTPASE
INHIBITOR
by
Leyla Akhadov
B.S., Chemical and Biological Engineering, University of New Mexico, 2019
M.S., Biomedical Engineering, University of New Mexico, 2020
ABSTRACT
Abnormal functioning of small GTPases is implicated in a variety of diseases, ranging
from neurological and developmental diseases to cancer. In fact, mutant GTPases are found in up
to 30% of cancers. Thus, small GTPases are a highly relevant target in drug discovery and
development. High-throughput targeted screening of small molecules is the most productive
method of discovering compounds that can give insights into drug development. This thesis
describes improvements made to a high-throughput GTPase-targeted screening method to
minimize confounding systematic error. It also describes the follow-up characterization of a
compound that was identified in a high-throughput screen. The compound under investigation,
PR-619, was shown to be a pan-GTPase inhibitor that competitively inhibits guanine nucleotide
binding in a panel of sixteen members of the Ras superfamily of small GTPases. Additionally,
PR-619 was demonstrated to inhibit GTPase-effector interaction and to produce effects in
cellular studies.
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CHAPTER 1: Introduction
1.1. Overview and Project Aims
Mutant GTPases have been associated with several human diseases and carcinomas 1–13.
Because of their involvement in cell signaling, aberrant activity in GTPases can lead to
excessive cell proliferation, motility, and other hallmarks of cancer. This, in addition to
their ubiquitous presence in nearly every cellular process, has made GTPases important
targets for therapeutics and molecular probes.
Dr. Sklar and collaborators have previously demonstrated the utility of a microsphere
bead-based high-throughput flow cytometry assay for the identification of GTPase
inhibitors and activators from screens of several molecular libraries 14–20. The assay can
be used for initial identification of GTPase-active compounds, followed by rapid dose
response generation and real-time kinetic studies of identified compounds. The assay has
also been adapted into a multiplex form in which multiple GTPases can be analyzed at
once, further increasing the rate at which compound libraries can be screened. However,
there is evidence that the multiplex assay allows cross-contamination of GTPases, leading
to confounding systematic error.
The first of the two primary objectives addressed in this thesis was to improve the
existing multiplex screen by preventing cross-contamination of proteins between beads.
This objective was met by increasing site occupancy on the microsphere beads, thereby
minimizing the available sites where cross-contaminating proteins may adhere after
dissociating from the microsphere to which they were originally bound. These
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adjustments were applied in a compound library screen using the improved multiplexed
system.
The second objective of this work was to characterize a compound that had been
identified as a pan-GTPase inhibitor in a previous compound library screen. The inhibitor
under investigation, PR-619, was characterized for its mechanism of inhibition, inhibition
of effector binding, and intracellular GTPase inhibitory activity. Collectively, these
results present PR-619 as a novel competitive inhibitor of a broad spectrum of Ras
superfamily GTPases with potential for use as a molecular probe.

1.2. Background
1.2.1. GTPases
GTPases are intracellular enzymes loosely anchored to the plasma membrane that act as
binary molecular switches for a variety of cellular processes. GTPases can be split into
two broad classes: heterotrimeric G-proteins, and monomeric small GTPases 1,2,21,22. Both
classes transmit signals from cell membrane receptors to intracellular targets. All
GTPases, regardless of class, perform the same function: to bind and hydrolyze
guanosine triphosphate (GTP) to guanosine diphosphate (GDP). Downstream effects that
are regulated by signaling processes involving GTPases include activation of
transcription factors, cytoskeletal rearrangement via polymerization and
depolymerization, and other diverse responses.
Heterotrimeric G-proteins are associated with seven-transmembrane receptors (also
called G-protein coupled receptors, GPCRs). GPCR interaction with an extracellular
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ligand induces a conformational change in the receptor that subsequently allows for
activation of the heterotrimeric G-protein, which in turn initiates signal transduction.
Small GTPases are similar to heterotrimeric G proteins in their association with the cell
membrane and involvement in signal transduction. When bound to GTP, the GTPase is in
the active state and has an increased affinity for effectors that carry out signaling or
regulate cellular processes 1,7,21,22. Conversely, GDP-bound GTPases are inactive. These
states of activity relate to the ability of the GTPase to recruit effector proteins and carry
out downstream signaling: effectors can only interact with GTPases when the GTPase is
in the active state 8,9. Wild-type GTPases rest in the inactive state and are activated in
response to upstream signaling, but oncogenic and other disease-causing mutations can
leave GTPases constitutively active or inactive. All GTPases cycle between the inactive
and active states primarily by the mediation of two classes of regulatory proteins: guanine
nucleotide exchange factors (GEFs) and GTPase activating proteins (GAPs). When signal
transduction begins, GEFs remove the GDP from the nucleotide binding cleft, and the
high proportion of free GTP to GDP in the cell favors GTP loading onto the
GTPase 2,10,23. GTP binding induces conformational changes to the Switch 1 and 2

Figure 1.1. Schematic
depicting GAP-mediated
hydrolysis of GTP and GEFmediated replacement of GDP
for GTP.
3

regions of the GTPase, allowing it to bind to other regulatory and effector proteins to
transduce a signal (Figure 1.1). Because the intrinsic hydrolytic activity of GTPases is
typically low, GAPs, which enhance the enzymatic activity of the GTPase 100-fold 10, are
necessary to stimulate GTP hydrolysis to GDP, thus bringing the GTPase to its inactive
state and terminating the GTPase signal 23.
The Ras superfamily of small GTPases can be divided into five main subfamilies on the
basis of sequence and function: Ras (Rat sarcoma), Rho (Ras homolog), Ran (Ras-like
nuclear protein), Rab (Ras-like protein in brain), and Arf (ADP-ribosylation factor). All
members of the Ras family share a common biochemical mechanism and a set of
conserved residues in the nucleotide binding motif that make up the G domain, which is
responsible for both nucleotide binding and effector interaction 1,21. Of the five
subfamilies, the Ras subfamily, comprised of 36 members, is the most well-researched
because of its role in human oncogenesis 1,21. Ras GTPases are primarily implicated in
the regulation of gene expression and cell proliferation, differentiation, morphology,
survival, and apoptosis 1,7,9,21. The Rho subfamily, comprised of 20 members, is
responsible for the regulation of extracellular stimulus networks that regulate actin
organization, cell cycle progression, and gene expression. Notable members of the Rho
family include RhoA, Rac1, and CDC42 1,7,9. The Rab subfamily is the largest branch of
the Ras superfamily with 61 members. Rab proteins integrate signals relating to vesicular
transport and protein trafficking between organelles 1,7,9. The Arf family consists of 30
members that are involved in the regulation of vesicular transport 1,7. The Ran family
consists of only one protein but is the single most abundant small GTPase in the cell. It is
involved in nuclear transport of RNA and proteins 1,7,9.
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Each subfamily of GTPases has its own set of GEFs and GAPs, which are structurally
distinct but functionally similar across families 1. The Rho and Rab families have a third
family of activity regulators called guanine nucleotide dissociation inhibitors (GDIs),
which prevent GDP dissociation from GTPases by binding and sequestering the GTPase.
Additionally, each subfamily has a unique set of effector proteins that it can activate.
Because of the crucial roles that small GTPases play in cell signaling and other functions,
missense mutants can lead to a variety of diseases. Ras subfamily mutants, in particular,
are key players in both tumorigenesis and tumor maintenance 10, and as a result of their
high rate of occurrence in human cancers have been the most well-studied family of small
GTPases. Ras subfamily mutations are found in an estimated 15-30% of human
cancers 7,9,11,12,24, with an even larger incidence rate in specific types of cancer. Most
notably, KRAS mutations are found in 98% of pancreatic ductal adenocarcinomas 11, 1550% of lung cancers, and 50% of breast cancers 25. In fact, mutations in most GTPase
subfamilies are associated with neoplastic transformation, and individual subfamilies
have additional associations with other disorders in humans. For example, RAS
mutations are associated with a spectrum of developmental disorders 2,12, RHO mutations
with immunodeficiency syndromes 13, and RAB mutations with inherited neuropathies
and Alzheimer’s Disease 3. Because of the prevalence of GTPase gene mutations in
disease, small GTPases have been an aspirational therapeutic target for several decades.
However, there are still no clinically available drugs that target mutant GTPases,
although several are currently in clinical or preclinical studies 24,26.

5

1.2.2. Review of Related Literature
Historically, small GTPases have been considered “undruggable” for their smooth and
shallow binding sites 4,7,27,28 and their high affinity for guanine nucleotides 7, although
recent research has proven otherwise 16,19,29,30. One of the earliest GTPase inhibition
studies attempted to prevent Ras farnesylation, a posttranslational modification that
allows for membrane localization 5,7,31. Unfortunately, farnesyltransferase inhibitors
failed in clinical trials due to toxicity 5,7,31. More recent approaches include targeting
other binding sites on GTPases to prevent interaction with effectors, such as kinases, and
regulators, such as GEFs, or direct inhibition of the effectors and regulators
themselves 5,7,11,32,33. However, inhibition of effector and regulatory proteins instead of
the direct GTPase inhibition can lead to unexpected consequences: studies on
farnesylation inhibition, for example, were successful in biochemical systems but were
unsuccessful in vivo because of the existence of a previously undiscovered secondary
membrane localization system 5,7,11,32.
Several direct inhibitors of GTPase-nucleotide binding have been discovered 19,24,34,35.
GTPase targeting can occur directly, as both the drug and the nucleotide compete to bind
in the same site, or allosterically, as the drug binds to another site on the GTPase to
prevent or enhance GTPase activation. None of the GTPase-targeted drugs that have
reached preclinical or clinical trials are direct competitors for the nucleotide binding
cleft 24, possibly due to the long-standing belief that no inhibitory drug could compete
with the high affinity of GTPase to nucleotide and the high nucleotide concentration in
the cell 7,36. Nonetheless, GTP-competitive molecules that directly inhibit nucleotide
binding have been discovered and used as molecular probes 19,34,35,37.
6

1.2.3. Methods of GTPase Interrogation
Methods for the development and discovery of GTPase-inhibiting compounds include in
silico screening, usually in tandem with structure-based drug design 33,38,39, and in vitro
screening of drugs to inhibit the activity of GTPases, their effectors, or their regulatory
proteins. In vitro characterization is typically performed using solution-based
biochemical assays of purified GTPases (and sometimes associated regulatory proteins
and effectors) to monitor changes to fluorescent molecules as a result of GTPase
activity 33,40,41. However, biochemical assays generally require large quantities of purified
GTPases, as opposed to biochemical assays on kinases and GTPase effectors which
require up to a 1000-fold smaller concentration than small GTPase assays 33. This
difference arises from the low enzymatic activity of GTPases compared to kinases and
GTPase effectors 33 and makes direct GTPase inhibition assays costly.
Methods for direct measurement of GTPase-nucleotide binding include quantitative
assays, such as ligand overlay blotting, thin layer chromatography,
immunoprecipitation17, and real-time quantitative assays using time course-HPLC and
nuclear magnetic resonance (NMR) 42,43. However, these assays still require very high
GTPase concentrations 42 and are not cost-effective methods real-time GTPase activity
quantification.
To overcome the hurdles to high-throughput GTPase activity quantification, Dr. Sklar
and collaborators developed a bead-based assay for real-time measurement of GTPasenucleotide binding 17. In this method, GTPases are bound to microsphere beads,
effectively concentrating the GTPase at the bead surface and enabling analysis using flow
cytometry. The GTPases are treated with a fluorescently labeled nucleotide, facilitating
7

detection of nucleotide-bound GTPase, which is in turn bound to the microsphere bead.
This assay has been used with success in numerous chemical library screens, resulting in
the identification of several GTPase inhibitors and activators 14–20. This assay is discussed
in greater detail throughout this thesis.

1.3. Flow Cytometry
Flow cytometry is a laser-based technique originally developed for the analysis of single
cells 44,45 that has also been applied to detect microsphere beads and other particles
suspended in solution. Flow cytometry is unique in that it interrogates individual cells or
particles and can provide information on particle size and fluorescence, either as a result
of autofluorescence or fluorescent staining 45. Since its development in the 1970s, flow
cytometry has become a powerful and broadly applicable tool in the field of
biotechnology because of its unique ability to quantify the distribution of characteristics
in a population of particles 45.
A flow cytometer consists of three key systems: fluidics, optics, and electronics 44. The
fluidics system retrieves the liquid sample and injects it into a stream of sheath fluid in
laminar flow, resulting in hydrodynamic focusing of the sample stream. Ideally, the
focused sample stream produces a single-file stream of particles, allowing for individual
interrogation of each particle. Interrogation occurs as the focused sample stream flows
past a laser beam directed orthogonally to the flow of the sample, and the resulting
scattered or fluorescent light from each particle is detected by a series of light sensors,
typically photomultipliers or photodiodes, which then convert the light signal into an
electronic signal 44,45.
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Upon interrogation, particles scatter visible light in both the forward and side directions.
The forward-scattered light provides information about particle size, while side-scattered
light can indicate particle size or cell granularity and morphology, among other
qualities 44,45. The laser beam also excites fluorescent molecules in the particles, which
can be used to tag individual populations of particles, allowing the populations to be
separated and analyzed individually, or which can be used to tag and detect specific
intracellular components within a single population 44,45. Most flow cytometers have
several light sensors, each with a different range of fluorescence emission wavelengths it
can detect. These individual channels enable measurement of multiplex scattering or
fluorescence signals from each detected particle. Analysis of flow cytometry data usually
involves selection (gating) of specific events of interest based on scatter or fluorescence
levels, followed by analysis of the full multi-parametric data set associated with each
gated event.

1.4. Overview of Thesis
The work described in this thesis is divided into two parts: first, the improvement of an
existing high-throughput screening system for detecting small molecules with activity on
small GTPases, and second, the characterization of a pan-GTPase inhibitor that was
identified using a high-throughput screen. Chapter 2 describes the methods, results, and
outcomes of the assay improvement process. Chapter 3 details the characterization of a
previously identified pan-GTPase inhibitor, PR-619. PR-619 was characterized in
biochemical assays to determine its mechanism of inhibition and ability to inhibit effector
binding, and in cellular assays, where its effects on intracellular GTPases and
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heterotrimeric G proteins were investigated. The final chapter of this thesis summarizes
the work and proposes future directions for research.
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CHAPTER 2: Multiplex Screen Improvement
2.1. Introduction
The discovery of new drugs in wet lab screening (i.e. not through computer-aided drug
design) is often performed in high throughput, where several hundred or thousand
chemicals, typically organized into compound libraries, are rapidly evaluated for
efficacy 46,47. These screens generally have a low hit rate, but can nonetheless be a
productive method for compound or drug discovery 46. Screening methodologies can be
divided into two categories: phenotypic and target-based screening. In phenotypic
screening, also known as classical pharmacology, whole cells or organisms are treated
with compounds and the phenotypic effects of the compounds are observed. In targetbased screening, also called reverse pharmacology, target proteins are selected prior to
the screen, and compounds are assessed for efficacy on those target proteins 47,48. There is
some overlap between the two screening methodologies with targeted cell-based
screening. Phenotypic identification of hits is followed by investigation into the
mechanism of the drug’s efficacy, while target-based hit identification is followed by
studies in cells, tissues, and whole organisms 47.
The target-based screen described in this chapter is designed for the rapid detection of
GTPase-inhibiting or -activating compounds in several GTPases at once. This involves
combining several GTPases that are sequestered by species on microsphere beads.
Maintaining this separation between GTPase species is crucial to this screening
methodology, as cross-contamination of GTPase species could lead to confounding
systematic error. This chapter details the process of improving the existing method for
multiplexed screening of GTPase-inhibitory compounds to prevent such anomalies.
11

2.2. Bead-Bound GTPase assay
This GTPase assay uses polystyrene microsphere beads of 4 μm diameter that have been
functionalized with glutathione (GSH). Each set of beads is colored with a fluorescent red
dye at varying intensities, allowing for separation of individual bead populations in a
multiplexed assay 14–20 (Figure 2.1, following page).
Individual bead sets of a single fluorescence intensity are coupled to fusion proteins of
GTPase with glutathione S-transferase (GST). GSH is a substrate of GST, enabling
adhesion of the GST fusion proteins to the GSH sites on the bead. To measure nucleotide
binding of the GTPase, GTPases are treated with a guanine nucleotide conjugated to a
fluorescent BODIPY-FL tag (referred to as BODIPY-GTP or BODIPY-GDP). BODIPYFL fluoresces green, so its presence on the bead can be detected in a separate detection
channel than the bead-associated red fluorescence when analyzed via flow cytometry.
Inhibition of GTPase-nucleotide binding can be quantified by the green fluorescence
intensity of each bead relative to a control. BODIPY-GTP shows significant quenching
when not bound to GTPase as a result of photoinduced electron transfer between
BODIPY-FL and nearby guanosine molecules 49. Thus, BODIPY-nucleotide is very
weakly fluorescent in solution, and there is no confounding fluorescent signal from the
solution itself.
In the multiplex assay for high-throughput screening, up to nine bead sets are coupled
with nine different GTPases. The beads are all combined and treated with the compound
under investigation before addition of the fluorescent BODIPY nucleotide. Inhibitory
compounds are expected to show reduced green fluorescence intensity on beads

12

Figure 2.1. Principles of multiplexed bead-based assay. (A) Individual microsphere beads with
surface GSH sites are coupled with a GST-GTPase fusion protein, adhering the protein to the bead. To
detect nucleotide binding, a GTP or GDP with a fluorescent BODIPY tag is used. (B) Each
microsphere bead, with varying red fluorescence intensity (FL4 channel), is coupled to a unique
GTPase and treated with BODIPY-GTP. (C) Bead populations can be selected in the FL4 channel
because of their varying red fluorescent intensities. (D) Then, the fluorescent intensity of BODIPY on
individual bead populations is measured in the FL1 (yellow-green) channel.
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compared to an untreated control, and activating compounds are expected to do the
opposite.

2.3. Methods
The microsphere preparation process has been described previously 14–20. The GSHfunctionalized beads were washed twice with Buffer 1 (1 mM MgCl2, 125 mM
ammonium sulfate, 1 mM DTT, 0.5 mM EDTA, 0.01% NP-40, 0.1% BSA, 20 mM
HEPES pH 7.5), resuspended in the buffer, and incubated for 20-30 minutes at room
temperature with gentle rotation to block nonspecific binding sites on the beads 50. The
beads were then collected via centrifugation, resuspended in a solution of a GST-GTPase
fusion protein, and incubated overnight at 4°C with rotation. After incubation, the beads
were collected and the supernatant removed, then washed twice in Buffer 1. In a typical
multiplex experiment, a bead set is included that has not been coated in GST-GTPase,
leaving the GSH sites empty. This “scavenger” bead serves to collect some of the GSTGTPases that dissociate from other beads during the experiment to prevent reassociation
with another bead.
2.3.1. GSH Site Occupancy
For determining the GSH site occupancy of beads, individual bead sets were combined
and diluted to 1800 beads per microliter in Buffer 1, with one sample containing proteincoupled beads and another uncoated beads. A stir bar was added to each sample, followed
by 100 nM GST-green fluorescent protein (GST-GFP), and the samples were incubated
at room temperature with constant stirring for 25 minutes before flow cytometric reading.
Percent coverage, a measure of GSH site occupancy, was calculated as
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𝐶𝑜𝑣𝑒𝑟𝑎𝑔𝑒𝑖 % = (1 −

𝑀𝐶𝐹𝑖, 𝑐𝑜𝑎𝑡𝑒𝑑
) ∗ 100%
𝑀𝐶𝐹𝑖, 𝑢𝑛𝑐𝑜𝑎𝑡𝑒𝑑

𝐸𝑞. 2.1

where MCFi is mean channel fluorescence for bead set i, and coated and uncoated
indicate bead sets that have been and have not been coated with GST-GTPase fusion
protein, respectively.
The scavenger bead in the multiplexed GST-GFP occupancy experiments consistently
yielded a percent coverage between 0% and -20%. Negative site occupancy would result
when the ratio

𝑀𝐶𝐹𝑖, 𝑐𝑜𝑎𝑡𝑒𝑑
𝑀𝐶𝐹𝑖, 𝑢𝑛𝑐𝑜𝑎𝑡𝑒𝑑

is greater than 1, i.e. the scavenger bead in the sample of

protein-coated beads is bound to more GST-GFP than the same bead in the sample of
uncoated beads. This anomaly may be due to the high concentration of free GSH sites in
the uncoated sample and the potential depletion of the GST-GFP in solution. In the GSTGTPase-coated sample, the total concentration of free GSH sites is much lower than in
the sample without GST-GTPase. At an estimated 1.2x106 GSH sites per bead, the
concentration of free GSH sites in the uncoated sample is approximately 3.6 nM. This is
in contrast to the protein-coated sample, where the concentration of free sites is estimated
at 1.4 nM using coverage data from Figure 2.4A. It is also possible that the calculated
negative percent coverage is the result of density-dependent fluorescence quenching on
the uncoated beads. To correct for this anomaly, the negative percent coverage is
subtracted from the calculated percent coverage for each protein.
2.3.2. BODIPY-Nucleotide Binding Measurement
To measure the capacity of each protein-coated bead to bind BODIPY-GTP, the bead sets
were combined as described previously and diluted to 200 beads per microliter in
Buffer 1. Then, either unlabeled nucleotide at 100 times the BODIPY-GTP concentration
15

Figure 2.2. Schematic depicting the methodology for measuring site occupancy by GST-GFP
fluorescence intensity and for measuring BODIPY-GTP binding to GTPases.

(negative control) or additional Buffer 1 were added to the beads and the samples were
incubated for 30 minutes at 4°C with rotation. After incubation, 30 μM BODIPY-GTP
was added to samples. The samples were incubated for 2 hours at 4°C with rotation, and
data was collected using flow cytometry.
2.3.3. Compound Screening
For multiplex compound screens, individual bead sets were combined and added to a
384-well plate containing either compound, DMSO (untreated control), or unlabeled
nucleotide (negative control) in each well. After 1 hour of incubation at 4°C with gentle
agitation, BODIPY-GTP was added at 30 μM and incubated for an additional 2 hours.
The plate was then analyzed cytometrically.
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2.3.4. Analysis Methods
The multiplex data can be separated into individual bead sets on the basis of red
fluorescence intensity on the FL4 channel. Green BODIPY-FL or GFP are read on the
FL1 channel. Thus, the bead fluorescence and nucleotide-binding fluorescence are read
on different channels, so there is no effect of bead color on BODIPY-FL or GFP
fluorescence measurement. Initial gating of cytometric data was performed using
HyperView software.
The activity of bead-bound GTPases is quantified by the relative BODIPY fluorescence
intensity of each bead. Each sample or plate of samples is accompanied by a negative
control, where the GTPase beads are treated with unlabeled nucleotide in 100-fold excess
of BODIPY-nucleotide. The green fluorescence intensity of the control is indicative of
non-specific binding of BODIPY-nucleotide to GTPase or the bead surface, i.e.
BODIPY-nucleotide binding to sites other than the GTPase nucleotide binding cleft. The
net (specific) BODIPY-nucleotide fluorescence intensity is calculated
𝑀𝐶𝐹𝑖, 𝑛𝑒𝑡 = 𝑀𝐶𝐹𝑖, 𝑐𝑜𝑚𝑝𝑜𝑢𝑛𝑑 − 𝑀𝐶𝐹𝑖, 𝑐𝑜𝑛𝑡𝑟𝑜𝑙

𝐸𝑞. 2.2

where MCFi, compound is the MCF of bead set i treated with the compound under
investigation, and MCFi, control is the MCF of bead set i treated with 100-fold excess of
unlabeled nucleotide. In this case, all bead sets are coated in GST-GTPase fusion protein,
unlike the experiment analyzed by Eq. 2.1.
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2.4. Results & Discussion
2.4.1. Assay Improvements
Traditionally, these high-throughput screens have been conducted with each bead set
coupled at the same molar concentration of GTPase relative to the number of beads:
1 μM GTPase per 1,000,000 beads in a volume of 20 μM, where each bead has ~1.2x106
GSH sites 18. However, for reasons that are not clear, not all GST-GTPase fusion proteins
show the same nucleotide-BODIPY fluorescence intensity or the same coverage of GSH
sites on the bead (Figure 2.4A-B). Although the inconsistent fluorescence intensity of
BODIPY-nucleotide between beads can be normalized by comparing the relative
fluorescence intensity of compound-treated sample to the untreated control, poor GSH
site coverage presents an issue in a multiplexed assay. Because kinetic equilibrium is not
static on the time frame of tens of minutes, GST-GTPases are constantly dissociating
from and re-associating with beads. If there are available sites on other beads, free GSTGTPases from one bead set may
associate with unoccupied sites on
another bead set, leading to systematic
error and an inability to discern the
effects of compounds on specific
GTPases (Figure 2.3). This error is
especially problematic in the case of
compounds with selective activity on
specific GTPases, where crossFigure 2.3. Schematic of cross-contamination error
in bead-based multiplex system.
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contamination would appear as a
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Figure 2.4. Site occupancy and BODIPY fluorescence intensity. (A) Site occupancy of each GTPasecoated bead in an eight-GTPase multiplex. GST-GTPase displayed irregular site occupancy despite
coupling under identical, standardized conditions (1 μM GST-GTPase, 1x106 beads, 20 μL volume, 18
hr coupling). Site occupancy was measured from the fluorescence of GST-GFP relative to control beads
not coated with GST-GTPase as described in the text. These specific GTPases were selected for the
multiplex for their relevance in carcinomas and other diseases. (B) BODIPY-GTP fluorescence of the
same multiplex as figure A, also showing irregular fluorescence for each bead, presumed to indicate
differences in GSH site occupancy or GTPase nucleotide binding affinity. MCF = mean channel
fluorescence. (C) Site occupancy improvements made to four GTPases selected for their poor site
coverage (<60%) in figure A. the x-axis label “1x” indicates standard coupling conditions, “2x”
indicates a 2-fold increase in protein concentration while all other coupling parameters are maintained,
etc. For all GTPases investigated, increasing protein concentration resulted in increases in site
occupancy. Site occupancy greater than 60% was achieved for all four proteins investigated.
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significant effect on the specific GTPase, and effects of a smaller magnitude on GTPases
on which there is actually no effect.
To reduce the concentration of free GTPase, each multiplexed experiment includes a
“scavenger” bead, one which has not been coupled to protein and is included as a highavailability site for dissociated GST-GTPases to bind. In multiplexed experiments, the
scavenger bead shows fluorescence on the same channel as BODIPY-FL, suggesting that
GST-GTPases do in fact dissociate from beads (Figure 2.4B). The presence of free GSTGTPase only presents an issue, however, if there are sufficient sites available on nonscavenger beads – in that case, free GST-GTPases may attach to the available sites, crosscontaminating proteins between beads.
Figure 2.4A shows the percentage of free sites on each bead set as measured by GSTGFP fluorescence intensity on protein-coupled beads. The threshold for adequate
coverage was set to 60% to ensure that over half of the sites on the bead were occupied
by the desired GTPase, and thus RhoA, Cdc42, Rac1, and the KRas Q61H mutant were
selected for coverage improvement.
First, the concentration of GTPase in the bead coupling reaction was increased to push
the equilibrium state toward a higher percent coverage of GSH sites, as described by the
equation 50

𝜃=

[𝐺𝑆𝑇 𝐺𝑇𝑃𝑎𝑠𝑒]⁄𝐾𝑑
1 + [𝐺𝑆𝑇 𝐺𝑇𝑃𝑎𝑠𝑒]⁄𝐾𝑑

𝐸𝑞. 2.3

where θ is site occupancy and Kd is the equilibrium dissociation constant of GST-GSH,
reported as 80 nM 51. This equation provides a theoretical motivation for increasing
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coupling concentration with the intent to increase the value of θ. Figure 2.4C shows
percent coverage assessed at several coupling concentrations, where 1x represents the
standard 1 μM GST-GTPase per million beads, 2x represents a 2-fold increase in protein
concentration, i.e. 2 μM GST-GTPase per million beads, and so on. These results show a
clear relationship between concentration and site occupancy: increased coupling
concentration results in increased site occupancy.
To determine whether the improvements to site occupancy were a result of reactant
quantity or density, the volume of the coupling milieu was reduced 4-fold while the
quantities of protein and beads were kept constant, thereby reducing the reaction volume
to increase reactant concentration without increasing reactant quantity. Reducing the
reaction volume had no apparent effect on site occupancy (data in Appendix B).
The standard multiplex assay protocol was changed to reflect the results in Figure 2.4C.
RhoA, Cdc42, and Rac1 were coupled at 3 times the standard protein concentration,
KRas Q61H at 4 times the standard, and all other proteins were coupled at the standard
coupling conditions.
2.4.2. Screening
In an application of the improvements made to the multiplex bead screening process, over
1,200 small molecules from the Prestwick Chemical Library were screened for GTPase
inhibitory or activating properties using the previously described methods to improve
bead site occupancy. In these screens, a compound identified as a pan-GTPase inhibitor
from a previous screen, PR-619, was used as a negative control. Dose response data from
the previous screens that identified PR-619 as an inhibitory compound can be found in
Appendix A.
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2.5. Chapter Summary and Conclusions
This chapter outlined improvements to a preexisting assay to minimize systematic error
that renders the multiplex methodology ineffective. Increasing the concentration of
protein present in the bead coupling milieu resulted in improved site occupancy of GSH
beads, which reduces the available GSH sites for dissociated proteins to bind in a
multiplex assay.
As bead coverage drops, it is possible that a variety of free GTPases from other beads
may associate with the low-coverage bead, leading to increased response resulting from
non-target GTPases on the incorrect bead. The results presented in this section show
successful improvement of GSH site occupancy to ensure that all protein-coated beads
show over 60% coverage.
However, this does not completely eliminate the possibility of protein crosscontamination between beads. Instead, it reduces the magnitude of error that results from
cross-contamination, since fewer available sites on the bead implies less adhesion of
dissociated GTPases to the bead. Thus, the results from the multiplex still include a
margin of error that is difficult to isolate or account for. Nonetheless, future multiplex
results will still provide qualitative information regarding the inhibitory or activating
effects of compounds. It is also understood that the quantity of free GTPase in solution is
significantly lower than the concentration of bead-bound GTPase, which again reduces
the possibility of cross-contamination so severe that the results are uninterpretable.
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CHAPTER 3: PR-619 Characterization
3.1. Introduction
PR-619 (3,5 dithiocyanatopyridine-2,6-diamine) is a reversible broad-spectrum
deubiquitinase inhibitor that has been used to study the involvement of deubiquitinating
enzymes in various cellular processes. It has also been reported to be a potent DNA
topoisomerase II poison 52.
PR-619 was identified as a pan-GTPase inhibitor in the Selleckchem L1700 Bioactive
Compound Library with an EC50 between ~2 and ~35 μM with inhibition demonstrated
on eight KRas GTPases and nine non-KRas GTPases (see Appendix A). In target-based
screening, it is typical for hit compounds to be characterized in follow-up studies.
This chapter describes the follow-up characterization of PR-619. First, PR-619 was tested
for autofluorescence and fluorescence quenching to confirm that the existing dose
response data was not the result of an artifact. Then, a biochemical assay was conducted
to determine the compound’s mechanism of GTPase inhibition, followed by an
assessment of the compound’s ability to inhibit GTPase-effector interaction. Finally, PR619 was used in two cell-based assays to assess cell membrane permeability, efficacy in
cells, and off-target cellular effects.

3.2. Methods
3.2.1. Solution-Based Quenching Investigation
To ensure that the observed GTPase inhibitory dose response was not an effect of
fluorescence quenching by PR-619, a solution-based biochemical assay was devised.
Solutions of 300 nM BODIPY-GTP, 50 μM PR-619, and a combination of both 300 nM
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BODIPY-GTP and 50 μM PR-619 were prepared in two buffers that were used for
biochemical bead-based studies of the compound: Buffer 1, described previously, and
NP-HPSE buffer (20 mM NaCl, 100 mM KCl, 1 mM EDTA, 1 mM DTT, 0.01% NP-40,
0.1% BSA, 30 nM HEPES pH 7.5).
The solutions were loaded into a 384-well plate and analyzed using a plate reader with a
fluorescence excitation wavelength at 488nm and emission at 520nm. Data were analyzed
as the average fluorescence intensity of replicate wells.
3.2.2. Bead-Based Kinetics
Rac1-covered beads were prepared as described previously. For kinetics experiments, the
beads were diluted to 100-300 per microliter of NP-HPSE buffer and agitated with a
magnetic stir bar throughout the assay. After beginning data acquisition, 30 nM
BODIPY-GTP or BODIPY-GDP was added to the sample tube, followed by addition of
compound or DMSO several minutes later. Ten minutes after compound addition,
unlabeled GTP or GDP was added.
The dissociation rates of BODIPY-nucleotide were calculated over the time period after
the addition of PR-619 or unlabeled nucleotide using a one-phase exponential decay
model. To calculate dissociation rate after compound addition, the kinetic data was
normalized to the untreated control (where only DMSO was added) by dividing the two
data sets, and the compound-mediated dissociation constant was calculated by fitting to a
one-phase exponential decay model using GraphPad Prism version 8.4.0 for Windows.
𝑌 = (𝑌0 − 𝑃𝑙𝑎𝑡𝑒𝑎𝑢) ∗ exp (−𝐾 ∗ 𝑡) + 𝑃𝑙𝑎𝑡𝑒𝑎𝑢
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𝐸𝑞. 2.4

Here, Y is the signal, in this case mean channel fluorescence, Y0 is the signal at time t=0,
the plateau is the signal at infinite time, K is the rate constant, and t is time. The start time
for exponential decay was set as the time of compound addition in the kinetic assay.
3.2.3. Cell-Free G-Trap Assay
This assay exploits the selective binding of GTPase effectors to active GTPases in order
to “trap” active GTPase on the surface of microsphere beads. The beads are coated with
an effector-GST fusion protein, and then treated with a solution of GTPase specific to
that effector. Only active GTPases will bind to the effectors on the bead, allowing for
flow cytometric analysis of the active GTPase in the solution.
Simons and Buranda et al 50,53,54 have previously published a version of this assay that
uses cell lysates as the GTPase source and anti-GTPase antibodies for fluorescent
labeling. The present study demonstrates this assay in a cell-free system to detect
displacement of fluorescent BODIPY-GTP or BODIPY-GDP from the guanine
nucleotide binding site and inhibition of GTPase-effector interaction as a result of PR619 treatment.
Prior to coupling of effector to beads, GSH microsphere beads were washed twice in the
intracellular mimic HPSMT buffer (30 mM HEPES, pH 7.4, 140 mM KCl, 12 mM NaCl,
0.8 mM MgCl2, 0.01% Tween-20) 50. The buffer was then replaced with HPSMT
blocking buffer (HPSMT with the addition of 0.1% BSA) and incubated at room
temperature with gentle rotation for 20 minutes to block non-specific binding sites on the
beads 50. The buffer was then removed and replaced with an effector protein solution.
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P21-activated kinase – p21 binding domain (PAK-PBD) was used as the effector for
selective binding to active Rac1. The beads were incubated overnight in a solution of
PAK-GST fusion protein in HPSMT blocking buffer at 4°C with gentle rotation. Using
30,000 beads per micromolar concentration of effector protein results in 99.6% coverage
of the bead surface, which can be calculated using the relation
𝐾𝑑 =

[𝐺𝑆𝐻]𝑒 [𝐺𝑆𝑇]𝑒
[𝐺𝑆𝐻 𝐺𝑆𝑇]𝑒

𝐸𝑞. 2.5

where [GSH]e and [GST]e are the equilibrium concentrations of unoccupied GSH sites
and free GST respectively, and [GSH-GST]e is the equilibrium concentration of the GSHGST complex. The equilibrium dissociation constant (Kd) of GST-GFP on GSH beads
has been published as 80 nM 50,51, and the GSH site density is estimated at 1.2x106 GSH
sites per bead 14.
After overnight incubation, the beads were washed three times with HPSMT and
resuspended in 100 nM Rac1 solution. Prior to introduction to the beads, soluble Rac1GST fusion protein was incubated for 30 minutes in the presence of either 3 μM
unlabeled GTP or GDP, 100 μM PR-619, or the drug vehicle DMSO. After incubation,
30 nM BODIPY-GTP or BODIPY-GDP was added to the solution and incubated for an
additional 30 minutes. Finally, the Rac1 solution was combined with the PAK-coated
beads and incubated for 2 hours at 4°C with rotation, then analyzed using flow
cytometry.
3.2.4. VLA-4 Integrin Activation
This assay has been published previously 37,55–57. U937 myeloid cells stably transfected
with a non-desensitizing formyl peptide receptor (FPR) (U937 ΔST cells, henceforth
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referred to as U937 cells) 57 were cultured to a density of 500,000-700,000 cells/mL in
RPMI medium containing 10% fetal bovine serum and 1% penicillin-streptomycin. For
each assay, 1 mL of cells was transferred to a test tube and stirred gently with a magnetic
stir bar for the duration of the assay.
30 seconds after beginning kinetic cytometric data collection, 25 nM LDV-FITC, an
integrin ligand coupled to a fluorescent tag, was added as an indicator of integrin
activation state; LDV contains an amino acid fragment of fibronectin and binds to VLA-4
with high affinity 16,58,59. After the FITC fluorescence intensity had stabilized, 100 nM NFormyl-methionyl-leucyl-phenylalanyl-phenylalanine (fMLFF) was added as a ligand for
the formyl peptide receptor (FPR), which initiates a signaling pathway to induce the
conformational change in VLA-4 from a low affinity to high affinity state 57. After 4
minutes of further data acquisition, either the drug under investigation or the drug vehicle
DMSO was added, followed by the addition of 1 μM unlabeled LDV two minutes later.
Previous publications that did not investigate LDV dissociation rate suggest maximum
integrin deactivation approximately 100 seconds after compound addition 19,35, informing
the timed addition of unlabeled LDV in the present assay at two minutes after compound
addition. The total volume percent of DMSO in cell solution was kept at or below 1%.
Kinetic data was acquired using flow cytometry and analyzed using HyperView and
GraphPad Prism. The LDV-FITC dissociation rates after LDV addition were analyzed as
two-phase exponential dissociation, with the fast and slow dissociation rates set at 0.06 s-1
and 0.01 s-1, respectively, in accordance with previously published data 55. This analysis
was performed using GraphPad Prism version 8.4.0 for Windows. Analysis yields a
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percentage of fast dissociation, which can be correlated with the percentage of low
affinity integrins on the cell surface.
3.2.5. Solubility Studies
Solubility of the compounds used in the integrin activation assay was measured using
flow cytometry. Warm RPMI in a test tube with a stir bar was placed under the sample
probe of a flow cytometer. After beginning data acquisition, the compound solution in
DMSO was added to bring the final concentration of compound to the concentration to be
used in the VLA-4 assay. Compounds that precipitated out of solution caused an increase
in events recorded by the cytometer. The volume percent of DMSO-compound solution
in the RPMI sample was kept at 0.7% to maximize percent DMSO in the assay sample
(and thereby maximize solubility) while keeping the total volume percent of DMSO in
the VLA assay below 1% (after the addition of 1 μL each of LDV-FITC, fMLFF, and
LDV in DMSO)
3.2.6. Calcium Mobilization
This assay measures the influx of calcium into the cytosol from endosolic stores as a
result of ligand binding to the heterotrimeric G-protein-coupled FPR 60–62 and has been
reported previously 61.
U937 ΔST cells were cultured to approximately 1x106 cells/mL as described previously.
For each assay, 5x105 cells were removed, collected via centrifugation, rinsed in warm
phosphate-buffered saline (PBS), and finally resuspended in warm PBS. The fluorescent
Ca2+ indicator Fluo4 was added at 21 nM and cells were incubated at 37°C for 30 minutes
while protected from light. After incubation, the cells were washed twice with PBS and
resuspended in warm RPMI without BSA or antibiotics. 5x105 cells were transferred to a
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test tube for each assay, and the bulk cell solution was kept at 37°C protected from light
until use.
Shortly after beginning data acquisition, the compound under investigation or the
delivery vehicle was added. The compound was added to each 500 μL sample as 0.5 μL
of 50 mM PR-619 in DMSO to each 500 μL sample. Several minutes later, fMLFF was
added at varying concentrations and the signal was allowed to return to baseline before
ending data acquisition. As a positive control, a sample of cells was treated with 4 μM
thapsigargin, which raises cytosolic calcium by inhibiting Ca2+ reuptake into the
endoplasmic reticulum 63. The thapsigargin control was measured both at the beginning
and end of each assay to record the decrease in cell responsiveness over time.

3.3. Results
3.3.1. PR-619 Fluorescence Artifacts
A solution-based assay was conducted to measure the autofluorescence and BODIPYnucleotide fluorescence quenching of PR-619. Figure 3.1 (following page) shows the
fluorescent effects of PR-619 in two buffers used in the bead-based biochemical assays
described in this work. The compound produced no autofluorescence and no significant
reduction in BODIPY-GTP fluorescence. Thus, the inhibitory effects of PR-619 observed
in biochemical studies are likely not an effect of fluorescence quenching, and the results
in the studies described in this section are not the result of autofluorescence.
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Figure 3.1. Autofluorescence and quenching of PR-619. Addition of 50 μM PR-619 to Buffer 1 and
NP-HPSE resulted in no autofluorescence. Addition of 50 μM PR-619 to 300 nM BODIPY did not
result in a statistically significant decrease in fluorescence in either buffer (two-tailed unpaired t-test,
α=0.05, n=3. * p=0.08, ** p=0.22). Error bars represent SEM.

3.3.2. Nucleotide Dissociation Kinetics
In order to investigate the inhibition mechanism of PR-619 on small GTPases, Rac1 was
chosen as a model GTPase for its availability and its relatively high affinity to BODIPYnucleotide (see Figure 2.4B).
In Figures 3.2A-B, treatment with 100 μM PR-619 results in a decrease in fluorescence
intensity of both BODIPY-GTP and -GDP-treated Rac1 beads compared to the DMSO
control. The addition of unlabeled nucleotide several minutes later results in a further
decrease in fluorescence intensity.
To account for the non-constant response observed after the addition of DMSO, the PR619-treated dataset was normalized to the control dataset, and the PR-619-induced
dissociation constant (Koff) of BODIPY-nucleotide was calculated (Figure 3.2C-D). The
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Figure 3.2. Nucleotide dissociation kinetics on Rac1-coated beads. (A) Kinetic data for the nucleotide dissociation
experiment. Fluorescent BODIPY-GTP is added at t=30s, followed by DMSO or a solution of PR-619 in DMSO at
t=600s. Addition of PR-619 induces nucleotide dissociation, observed as a decrease in fluorescence intensity.
Unlabeled GTP is added a t=1200s to competitively induce BODIPY-GTP dissociation from the GTPase. (B) The
same kinetic experiment as in figure A, but with BODIPY-GDP and unlabeled GDP. (C) Kinetic data for the PR619-treated samples, normalized to the DMSO-treated sample, from t=60s to t=1200s. Black overlying curves
represent the one-phase dissociation model applied to the system to calculate dissociation constant. (D) Normalized
kinetic data for the GDP system. (E) BODIPY-GTP dissociation and (F) BODIPY-GDP dissociation after the
addition of unlabeled nucleotide in the DMSO-treated sample. (G) Mean dissociation rate constants for BODIPYGTP dissociation induced by GTP and PR-619, showing an insignificant difference between means. Two-tailed
unpaired t-test, α=0.05, p=0.12, n=4. Error bars are ±SEM. (H) Mean dissociation rate constants for BODIPY-GDP,
showing insignificant difference between GTP and PR-619. Two-tailed unpaired t-test, α=0.05, p=0.18, n=2. Error
bars are ±SEM. (I) Structure of PR-619.
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BODIPY-nucleotide Koff after the addition of unlabeled nucleotide in 100-fold excess of
BODIPY-nucleotide was calculated from the DMSO-treated datasets (Figure 3.2E-F).
Analysis of the BODIPY-nucleotide dissociation kinetics yields two mean dissociation
constants of BODIPY-nucleotide, one as a result of treatment with PR-619 and the other
of treatment with unlabeled nucleotide (Figure 3.2G-H). Notably, the mean dissociation
constant was not significantly different between PR-619-treated and DMSO-treated Rac1
beads in both the GTP and GDP systems. This indicates that the PR-619 and guanine
nucleotide have the same mechanism of BODIPY-nucleotide displacement 34, signifying
that PR-619 is a competitive inhibitor of the guanine nucleotide binding site.
3.3.3. Effector Interaction
To investigate the ability of PR-619 to inhibit GTPase-effector interaction, PAK-coated
beads were treated with GST-Rac1 that had been previously treated with either PR-619,
unlabeled nucleotide, or DMSO, then with 30 nM BODIPY-nucleotide. Because GTPase
effectors can only bind GTPases in the active state, the PAK-coated bead assay “traps”
active GTPases from solution – hence the name G-trap. In this study, GTPases are
activated with fluorescently labeled nucleotide, allowing for detection of PAK-bound
active GTPases. This is in contrast to previous reports of this assay, which use fluorescent
antibodies 19,50,53,54.
Figure 3.3 shows the inhibitory effect of PR-619 on effector binding as a reduction in
fluorescence intensity compared to the DMSO-treated control in the GTP system.
However, the bead fluorescence intensity after PR-619 treatment is greater than the
fluorescence intensity of the negative control, which was treated with unlabeled
nucleotide. This indicates that PR-619 at 100 μM only partially inhibits nucleotide
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Figure 3.3. Biochemical G-trap assay. PAK effector beads were treated with solutions of GST-Rac1
that had been previously incubated with either DMSO as a control, PR-619, or unlabeled nucleotide,
then with BODIPY-nucleotide. In both the GTP and GDP systems, PR-619 produced a decrease in
BODIPY fluorescence intensity, indicating inhibition of Rac1-effector binding. Error bars are SEM. *
n=4, ** n=2.

binding. In the GDP system, the DMSO-treated control exhibits non-zero fluorescence
due to the use of Rac1-GST protein; since BODIPY-GDP-conjugated Rac1-GST itself is
able to bind to unoccupied sites on the bead, but is unable to bind to the effector, the
observed fluorescence in this case represents bead-bound Rac1. As a result, Rac1 bound
directly to the bead is indistinguishable from Rac1 bound to the effector. Thus, the results
in Figure 3.3 represent some combination of both Rac1 states. Nonetheless, these results
indicate that PR-619 displaces the fluorescent nucleotide and at least partially inhibits
Rac1 binding to PAK-PBD. Future variations of this assay would benefit from the use of
Rac1 that is not a GST fusion protein, a reagent that was not available in our laboratory at
the time of this work.
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3.3.4. Cell-Based Assays
To assess the in vivo efficacy of PR-619 as a small GTPase inhibitor, two assays were
used, both of which stimulate the formyl peptide receptor (FPR). In the VLA-4 integrin
activation assay, FPR stimulation begins a signaling cascade that is known to involve
several small GTPases 64–66. However, the FPR is a G-protein coupled receptor, meaning
its stimulation and signal initiation capabilities are dependent on heterotrimeric G
proteins; thus, the observed effects of PR-619 in the VLA-4 activation assay could be a
result of off-target effects on heterotrimeric G proteins. To quantify these potential offtarget effects, a calcium mobilization assay was used, in which FPR stimulation results in
a measurable efflux of Ca2+ from the endoplasmic reticulum into the cytosol of the cell.
Changes in calcium flux into the cytosol as a result of PR-619 treatment would suggest
off-target effects.
3.3.4.1. VLA-4 Integrin Activation
To investigate the ability of PR-619 to both enter the cell membrane and inhibit small
GTPases in cells, a VLA-4 integrin activation assay was conducted. The integrin affinity
regulation pathway has been shown to involve the Rho-family GTPases Rac1 and
Cdc42 64,65 and Rap GTPases 66, as well as the G-protein-coupled FPR. Inhibition of
integrin activation by PR-619 and other compounds is considered indicative of the
membrane permeability and intracellular efficacy of the compound.
The VLA-4 activation pathway exploited in this assay begins with binding of formyl
peptide to FPR. This initiates an inside-out signaling pathway resulting in a
conformational change of the integrin that increases the integrin’s affinity for ligand.
Integrins are considered to exist in several conformation-dependent states relating to
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high, low, and intermediate affinity for ligand. In fluorescent integrin ligand studies, such
as this study, it is not possible to discern whether all of the integrins on a cell surface are
in the intermediate affinity state or if a fraction of integrins are in a high-affinity state
while another fraction is low-affinity 58. Thus, integrin ligand dissociation is assumed to
be a biphasic system for these purposes.
LDV-FITC, a fluorescently tagged VLA-4 ligand, binds to low-affinity VLA-4 with a Kd
of ~12 nM and to high-affinity with a Kd of ~1-2 nM 57. Thus, at 25 nM LDV-FITC, both
high and low affinity integrins are saturated. When unlabeled LDV is added in excess of
LDV-FITC, the latter will dissociate at a greater rate from low-affinity integrins than
high-affinity integrins—the lower the affinity of a ligand-receptor complex, the greater
the dissociation rate constant, koff 67,68. This principle enables kinetic measurement of the
average integrin activation state. Thus, if the compound has inhibited the GTPases in the
integrin affinity regulation pathway to block integrin activation, the dissociation rate of
LDV-FITC will increase to reflect integrin deactivation.
This study also included CID1067700 and ML-141, two compounds that have been
previously reported as GTPase inhibitors. Special attention was paid to the solubility of
all compounds in this assay to maximize the potential for cell membrane permeability.
Because this assay is performed on living cells, it is important to keep the total DMSO in
the sample at or below 1%, as DMSO concentrations above 1% can reduce monocyte
viability and responsiveness 69,70. Since the other reagents added during the assay bring
the volume of DMSO in the assay sample to 0.3%, the volume of compound solution in
DMSO added cannot exceed 0.7%. The assay concentrations of ML-141 and
CID1067700 were selected based on previous publications 19,20,35, and the volume of
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compound solution in DMSO was 0.7% for all compounds. The 70 μM concentration of
PR-619 was chosen as a maximum soluble concentration without exceeding 1% DMSO.
Figure 3.4A shows the precipitation of compounds in DMSO when added to 37°C RPMI,
measured as the change in event count recorded after compound addition. 30 μM ML-141
produces precipitate when added as 0.7% of the total sample volume, implying a
dissolved concentration much lower than 30 μM. PR-619 also produces precipitate when
added as 0.14% of the total sample volume to a final concentration of 70 μM, but
produces minimal precipitate when the total volume of DMSO in the sample is increased
to 0.7%, thus informing the decision to use 70 μM PR-619 in the VLA-4 activation study.
CID1067700 shows little to no precipitation upon addition to RPMI at 50 μM.
Figure 3.4B shows the kinetic VLA-4 assay data with timed addition of reagents. In
previous studies of CID1067700 and ML-141 in a VLA-4 activation assay, a decrease in
fluorescence intensity was observed either transiently, as in the case of CID1067700 35,
or persistently, as in the case of ML-141 19. Those effects are not observed here. This can
be attributed to the use of 4 nM LDV-FITC in those studies, a concentration that is
between the equilibrium dissociation constants of low and high affinity state integrins. In
that system, when integrins change from the active to inactive state, LDV-FITC
dissociates from the newly deactivated integrins, which presents as a loss of fluorescence.
Because 25 nM is above both the equilibrium dissociation constant of high and low
affinity state VLA-4, dissociation is not expected to occur when integrins change
activation state. Instead, this change would be observed as an increase in the dissociation
rate.
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Figure 3.4. VLA-4 integrin activation assay. (A) Solubility of PR-619, ML-141 and CID1067700 in
37°C RPMI. Percentage values are the percent DMSO in the RPMI sample after addition of the DMSOcompound solution. Elevated event counts suggest compound precipitation. (B) Kinetic data from
VLA-4 integrin activation assay on U937 cells. LDV-FITC, a fluorescent integrin ligand, is added at
t=30s, followed by fMLFF at t=120s to activate integrins. DMSO or compound dissolved in DMSO is
added are t=360s, then unlabeled LDV to induce dissociation of LDV-FITC at t=480s. Data staggered
for visibility. (C) Mean percentages of fast dissociation as calculated using a two-phase dissociation
model in GraphPad Prism. The means of CID1067700-treated and ML-141-treated samples were not
significantly different from the DMSO-treated control (two-tailed unpaired t-test, α=0.05, n=4, p=0.30
and 0.40 respectively). A statistically significant difference in mean percent fast dissociation for PR619 treated sample was observed (p=0.046). (D) structure of CID1067700. (E) Structure of ML-141.
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Dissociation rates were analyzed as two-phase dissociation, with the fast dissociation
representing dissociation from low affinity-state integrins and slow dissociation from
high affinity-state integrins. The calculated percent fast dissociation can be correlated to
the relative amounts of high and low affinity integrins on the cell surface. No significant
difference was observed in the percentage of fast dissociation between the DMSO control
and the samples treated with ML-141 or CD1067700 (Figure 3.4C). However, the PR619-treated shows a statistically significant decrease in the percent fast dissociation
relative to the DMSO control, implying activation of cell surface integrins in response to
PR-619 treatment, an unexpected effect for an inhibitory compound.
The observed insignificant changes as a result of treatment with ML-141 and
CID1067700 may contradict previously published results indicating integrin deactivation
as a result of compound treatment 19,35. The principle differences between the study
reported here and the previously reported study include the use of 4 μM LDV-FITC as
opposed to 25 μM LDV-FITC, as previously discussed, and the special attention paid to
compound solubility. The previous study on ML-141 uses a lower percentage of DMSO
(total 0.6%) 19, which would lead to lower compound solubility than what is reported
here. Since the compound is sparingly soluble in water 71, then it is possible that the
intracellular concentration of the compound is not high enough to produce a significant
effect on percent fast dissociation. However, this conclusion would benefit from further
experimentation to determine the precise solubility of ML-141 in water and the
intracellular concentration of compound. The data in this study alone do not support the
hypothesis that ML-141 treatment of myeloid cells results in VLA-4 integrin inactivation.
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In the case of CID1067700, previous publications reported a transient decrease in
fluorescence intensity ~100s after treatment with compound, followed by a return to
baseline fluorescence by ~300s after compound addition 35. It is possible that the
CID1067700 is quickly replaced by GTP or GDP in the cell due to the high
concentrations of both nucleotides relative to the intracellular concentration of the
compound. In this study, unlabeled LDV was added 120s after compound, and the kinetic
analysis of LDV-FITC dissociation was performed over the 7-minute span after LDV
addition. Since the effects of CID1067700 were observed to be transient over a period of
less than 300 seconds, the inhibitory effects are not expected to persist over the 7-minute
analysis period of this study. The transience of the CID1067700 inhibitory response
could explain the statistically insignificant difference in mean percent fast dissociation
from the control.
The data in Figure 3.4C may also suggest that this assay method is ineffective in
quantifying small changes to VLA-4 activation, since the small fluorescence changes that
were observed in previous studies of ML-141 and CID1067700 are not reflected in this
data.
PR-619 produced a statistically significant decrease in the percentage of fast dissociation,
i.e., an increase in high affinity-state integrins on the cell surface compared to the
untreated control. This suggests integrin activation, which contradicts the results of the
biochemical studies on this compound. There is evidence that integrin activity regulation
is mediated by a negative feedback system in which high-affinity integrins activate
phosphatidylinositol 3-kinase (PI3K), which in turn activates ARAP3, a GAP for Rho
and Arf GTPases, and the integrin is reverted to the inactive conformation 72. PI3K is a
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direct effector of activated small GTPases 6,73,74, requiring interaction with activated Rho
GTPases to become activated. Integrin signaling also activates Ras to initiate the MAPK
and PI3K/Akt signaling pathways 75. Thus, it would follow that inactivation of Rho
GTPases by PR-619 could prevent the negative feedback loop that controls integrin
inactivation, leading to a higher proportion of active integrins in the PR-619-treated case
than in the DMSO control. Confirming this possibility, however, would require further
investigation.
3.3.4.2. Calcium Mobilization
It is established that FPR-ligand interaction induces an increase in cytosolic calcium as a
result of the emptying of intracellular calcium stores 76–79. The resulting elevation in
cytosolic calcium leads to the activation of kinases and other enzymes, making calcium
signaling an important step in signal transduction 77,78. The chain of events from FPR
stimulation to cytosolic calcium increase begins with the activation of heterotrimeric G
proteins that are coupled to the formyl peptide receptor. To resolve whether the observed
effect of PR-619 in the VLA-4 assay is an effect of small GTPase inhibition or off-target
heterotrimeric G protein inhibition, the calcium flux in response to FPR stimulation was
measured both with and without PR-619 treatment.
No significant difference was observed in the mean calcium fluorescence peak between
PR-619-treated and DMSO-treated samples at several concentrations of fMLFF (Figure
3.5A). Note, however, that this observation comes with caveats which are discussed later
in this section. The PR-619 response was consistently lower than the DMSO control peak
response, but this can be attributed to the order in which experiments were conducted.
Because the DMSO control was always analyzed before the PR-619 sample, there was a
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Figure 3.5. Calcium mobilization assay. (A) Maximum fluorescence achieved as a result of fMLFF
treatment of PR-619-treated samples, shown as percent of the DMSO-treated control, at three
concentrations of fMLFF. Maximum fluorescence was calculated as the average of the 20 data points
with the highest fluorescence after fMLFF addition. No statistically significant difference was observed
between the mean maximum MCF of the DMSO control and PR-619-treated sample for each fMLFF
concentration (two-tailed unpaired t-test, α=0.05, n=2, p=0.90, 0.46, 0.64 in order from left to right).
(B) Representative kinetic data showing treatment of U937 cells with DMSO or a PR-619 solution in
DMSO at t=30s, then fMLFF treatment at t=270s, and the resulting fluorescence peak. (C)
Fluorescence peak induced by thapsigargin treatment, used as a positive control before and after
running test samples. Initial and final samples were conducted ~2 hours apart. A large decrease in
calcium response over the two-hour course of the experiment is evident. (D) Precipitation of PR-619
under these experimental conditions, observed as an increase in events recorded by flow cytometry.

time difference of approximately 15 minutes between the formyl peptide addition of each
sample. Figure 3.5C reveals a drastic decrease in calcium responsivity as a result of
thapsigargin-induced calcium efflux over the course of the experiment. The time between
the initial and final thapsigargin-treated samples was less than two hours. Thus, the 1020% decrease in peak calcium response between the DMSO-treated and PR-619-treated
samples can easily be attributed to the rapid decrease in calcium responsivity. The decay

41

in maximum fluorescence intensity can be ascribed to the action of organic anion
transporters that actively remove the fluorescent calcium indicator from the cytosol and
into the extracellular space 80. Thus, the fMLFF-independent and statistically
insignificant but consistent decrease in fluorescence intensity observed in PR-619-treated
samples is considered a result of the time difference between the cytometric analysis of
the DMSO-treated control and the PR-619-treated sample, and not a result of PR-619
treatment.
These results come with several caveats that render this data suggestive but inconclusive.
Most importantly, this study was conducted under conditions that led to PR-619
precipitation, as shown in Figure 3.5D. PR-619 solution was added as 0.1% v/v DMSO in
the sample to a final concentration of 50 μM. The precipitation of the compound under
these conditions was not known at the time of experimentation. Due to unforeseen time
constraints, repetition of these experiments under conditions that ensure compound
solubility was not possible. Additionally, this study was conducted using 50 μM PR-619,
whereas the VLA-4 activation assay used 70 μM PR-619. Even if the compound was
soluble under these conditions, the lack of effects observed from PR-619 treatment may
be a result of insufficient compound concentration. This makes it difficult to conclude
whether the effects of PR-619 observed in the VLA-4 activation assay were related to
effects on heterotrimeric G proteins.
Thus, this study alone cannot lead to the definitive conclusion that PR-619 does not affect
heterotrimeric G proteins. An optimization of this study in which PR-619 is used under
soluble conditions and at 70 μM would be necessary to draw this conclusion.
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3.4. Chapter Summary and Conclusions
This chapter described four methods for characterizing and validating the inhibitory
activity of PR-619. In a bead-based biochemical experiment, both the compound and
unlabeled nucleotide showed a statistically insignificant difference in the rate of
fluorescent nucleotide inhibition, suggesting that PR-619 inhibits in a competitive
manner. The results of an effector-based assay suggested that PR-619 also inhibits
effector binding. Both of these biochemical assays successfully demonstrate that PR-619
is an inhibitor of small GTPases.
Cell-based experiments showed mixed results. An integrin activation assay surprisingly
exhibited the opposite of the expected effect of PR-619 treatment, but it is possible to
rationalize this observation while maintaining the hypothesis that PR-619 is a panGTPase inhibitor in cells. Although PR-619 treatment did not inhibit calcium
mobilization, the study itself was flawed in that PR-619 was not fully solubilized.
Therefore, it is not possible to conclude whether PR-619 acts on heterotrimeric G
proteins.
The results presented in this chapter would greatly benefit from further investigation. The
calcium mobilization assay suffered from a rapid decrease in fluorescence intensity, as
well as the precipitation of the compound under the assay conditions. To improve on this
assay, cells could be treated with the organic anion transporter inhibitor probenecid to
prevent the displacement of the fluorescent calcium indicator observed over the course of
the experiment. Additionally, the compound could be added as a greater volume of a
reduced concentration PR-619 solution in DMSO, as in the VLA-4 assay, since those
conditions were shown to promote compound solubility.
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One additional study to confirm the efficacy of the compound in cells might include a
cell lysis G-trap assay, in which effector-coated microsphere beads are incubated in cell
lysate from PR-619 treated cells. The effector “traps” active GTPases on the bead, which
are then detected using labeled antibodies. Studies of this type have been previously
published 50,53,54 and have been used to verify efficacy of other GTPase inhibitors in
cells 19. This study would also verify the cell membrane permeability of PR-619 in the
myeloid cell line used in the cell-based studies presented here. Applying the G-trap assay
to the other inhibitory compounds studied in the VLA-4 integrin activation assay, Ml-141
and CID1067700, would also verify whether the observed insignificant change in integrin
activation is evidence of ineffective inhibitory compounds or an artifact of an insensitive
assay method.
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CHAPTER 4: Summary and Future Directions
4.1. Summary of Work
Aberrant activity of small GTPases has been implicated in several diseases, making
GTPases a relevant focus of biomedical research. This thesis described a high-throughput
screening assay to identify drugs that act on small GTPases and the follow-up studies on
a compound identified from such a screen.
High-throughput screening assays must be consistent and of high quality to enable the
rapid compound screening that high-throughput drug discovery entails. The work
described in this thesis describes investigation into a source of systematic error in this
system and the amelioration of that error. Specifically, protein displacement from beads
in the multiplex system was observed as a non-zero green fluorescence on an uncoated
bead. Re-association of proteins with other beads in the multiplex would lead to
confounding results. The improvements made to the multiplex system demonstrated a
successful increase in bead site occupancy, which in turn leads to a decreased likelihood
of free-protein association with those beads. These improvements to the multiplex were
implemented to screen a library of several hundred small molecules.
A pan-GTPase inhibitory compound identified in a previous screen, PR-619, was
characterized for biochemical inhibitory activity and activity in cells, as is typical for hits
from targeted screens. Biochemical studies of the compound’s inhibition kinetics
demonstrated a competitive mechanism of action, and another biochemical study
suggested inhibition of GTPase-effector binding. Cellular assays showed an unexpected
effect on an integrin activation pathway. A further cell-based study attempted to
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investigate whether PR-619 produces off-target effects on heterotrimeric G proteins, but
flaws in the experimental methodology rendered those results inconclusive. As
previously discussed, the cell-based studies presented here would greatly benefit from
additional investigation to resolve the unexpected effects that were observed.

4.2. Future Directions
The improvements made to the multiplex GTPase screen have helped make the system
more accurate and applicable in high throughput screening. We anticipate the use of this
improved multiplex in screens where compound quantities are limited, a condition that
would rule out the possibility of non-multiplex single-GTPase assays.
The data presented in Chapter 2 (Figure 2.4C) were collected in a partial multiplex. To
verify the site occupancy improvements, the improved eight-protein multiplex was
assembled and its site occupancy and BODIPY fluorescence intensity were measured. In
Figure 4.1A, three out of the four targeted GTPases did not show the improvements in
site occupancy that were observed in Figure 2.4C. Because the data in Figure 4.1 are
representative of one biological replicate, it is possible that further replicates of the
multiplex would reveal an improvement in site occupancy on average. Despite not
showing significant improvement in bead coverage, all four of the selected GTPases did
show improvements in BODIPY-nucleotide fluorescence intensity, implying a greater
capacity to bind nucleotide. This may be due to the free GST that is a known contaminant
of the commercially prepared Rac1, RhoA, and Cdc42 used in this multiplex 81–83, since
free GST occupying GSH sites would be indistinguishable from GST-GTPase in this
non-kinetic site occupancy experiment. It is possible that increasing the concentration of
protein in the coupling milieu allows a greater proportion of GST-GTPase to occupy
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GSH sites, which would appear as an increased BODIPY fluorescence intensity.
Unfortunately, due to unforeseen time constraints, investigation into this phenomenon
was not possible.
This multiplexed GTPase assay would greatly benefit from continued optimization and
verification of the obtained results in the full multiplex. Without the opportunity for
further optimization, we determined that the collective results presented in Figures 2.4C
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Figure 4.1. Eight-protein multiplex site occupancy and BODIPY fluorescence, before and after
improvements. (A) Site occupancy of the four GTPases that were selected for coverage improvement
are shown in shades of blue (RhoA, Cdc42 WT, KRas Q61H, Rac1). Of the four GTPases, only KRas
Q61H showed occupancy improvement in this mixed multiplex experiment. (B) BODIPY-GTP
fluorescence at 30 nM. Paradoxically, all four of the selected proteins showed increases in BODIPY
fluorescence, despite no improvement in percent site occupancy for three out of the four GTPases.
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and 4.1 were demonstrative of sufficient improvement to the multiplex system such that a
chemical library could be screened, and then screened the library. Before pursuing future
screens, a re-assessment of the full multiplex under the improved coupling conditions for
RhoA, CDC42, Rac1, and KRas Q61H is recommended.
The results of the PR-619 characterization studies would also benefit from augmentation
by further experiments. As previously mentioned, the biochemical G-trap assay would be
improved by the use of Rac1 that is not a GST fusion protein. Also discussed was the use
of a cell lysate-based G-trap assay. The ambiguous results produced by the VLA-4
integrin activation study could be explored by using a reduced concentration of LDVFITC, which would allow the fluorescent molecule to dissociate from the integrin as the
integrin changed in conformation. This adjustment would also permit observation of
transient effects as a result of compound treatment 16. The calcium mobilization assay
produced uninterpretable results because of the precipitation PR-619; it follows that the
assay would benefit from efforts to improve PR-619 solubility.
In any screen of a small molecule library, the desired outcome is to produce compound
hits with potential for use in medicine or as a molecular probe. Studies on PR-619 as a
deubiquitinase inhibitor have demonstrated cytotoxicity with prolonged exposure 84,85,
making it unlikely that PR-619 has potential for clinical use. However, PR-619 can be
used as a control compound and molecular probe in future studies. In fact, PR-619 was
used as a control inhibitory compound in a recent chemical library screen, demonstrating
its potential for use as a proven GTPase inhibitor. This compound may serve as a starting
point for the development of GTPase inhibitory compounds with clinical applications.
Another potential application for PR-619 is as a molecular probe. Since the compound
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inhibits a broad spectrum of GTPases (see Appendix A), it could be used in cell-based
studies to selectively remove GTPase activity from signaling cascades in order to further
define the specific roles that GTPases play in cell signaling pathways. There are currently
relatively few compounds capable of inhibiting Rab GTPases, lending this compound
specific utility as a molecular probe 34,35,37.
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APPENDIX A: PR-619 Dose Response
The data in this appendix is the work of Harold Ames, Dr. Mark Haynes, and Dr. Anna
Waller.

PR-619 inhibits BODIPY-GTP binding to several KRas mutants and several nonKRas GTPases. Samples were prepared as described in Section 2.3.3 with the use of
10 μM BODIPY-GTP. Error bars represent ±SEM. Data points are fitted with a fourparameter, variable-slope [inhibitor] vs dose response curve using GraphPad Prism
8.4.0 for Windows. The calculated EC50 values are in the table below.
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Non-KRas
KRas GTPases

EC50 (M)

EC50 (M)
GTPases

KRas WT

1.9x10-5

Rab7

2.1x10-5

KRas G12V

2.9x10-5

RhoA

2.1x10-6

KRas G12A

3.4x10-5

HRas WT

7.3x10-6

KRas G12C

1.7x10-5

Cdc42 L61

7.3x10-6

KRas G12D

2.4x10-5

HRas V12

2.2x10-5

KRas Q61H

1.6x10-5

Rac1 L61

8.8x10-6

KRas Q61L

2.2x10-5

Cdc42 WT

7.3x10-6

KRas Q61R

2.9x10-5

Rac1 WT

1.1x10-5
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APPENDIX B: Site Occupancy Supplemental Data
The data below shows the results of a four-fold reduction in coupling volume from the
standard multiplex preparation protocol, which calls for 1 μM GST-GTPase per 1x106
beads in 20 μL volume to be coupled overnight (~18 hr). In the reduced volume case, all
parameters were kept the same except the coupling volume, resulting in coupling at 4 μM
GST-GTPase, 1x106 beads in 5 μL volume, coupled overnight (~18 hr). The figure below
shows minimal improvement in coupling for all GTPases studied.
Due to limited resources, some of the GTPases present in the eight-GTPase multiplex
discussed in Chapter 2 were omitted in this experiment. The KRas WT sample prepared
as in the standard multiplex protocol was lost during the sample preparation process.
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